Abstract
Posttraumatic stress disorder (PTSD) is a debilitating disorder that affects around 8% of the U.S. population (1). PTSD is characterized by a variety of symptoms, including hyperarousal/vigilance, difficulty sleeping, and intrusive thoughts related to the traumatic event that can be extremely debilitating to the individual. The current medications for PTSD that are approved by the U.S. Food and Drug Administration are limited to selective serotonin reuptake inhibitors or norepinephrine reuptake inhibitors, which are only moderately effective and do not help the majority of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
